CGRP Antagonist Tablet with PVP/VA Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing a stable pharmaceutical formulation for CGRP antagonists with low solubility, particularly in solid form for oral administration, is challenging due to their poor aqueous solubility and high melting points, which hinders effective oral drug absorption and immediate release.
Innovation Solution
A tablet formulation comprising a water-soluble polyvinylpyrrolidone/vinyl acetate copolymer matrix with a dispersing agent like TPGS and a disintegration system of powdered sodium chloride and croscarmellose sodium, which achieves complete disintegration within 5 minutes and releases at least 90% of the compound in less than 20 minutes, enhancing bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If a solid formulation is used for oral administration, then stability and ease of administration are improved, but solubility and absorption rate deteriorate
Solution Approach 1:
The patent changes the physical state of the API from crystalline to amorphous, and disperses it within a polymer matrix, fundamentally altering its dissolution behavior. The amorphous state eliminates crystal lattice energy barriers, while the polymer matrix provides sustained solubility enhancement, resolving the contradiction between solid formulation stability and oral absorption reliability.
Solution Approach 2:
The invention creates a composite material system consisting of the CGRP antagonist API dispersed within a polymer matrix (such as HPMC or PVP). This composite structure combines the stability of the solid polymer matrix with the enhanced solubility properties of the amorphous API dispersion, simultaneously achieving both formulation stability and improved oral absorption.
2Reliability
If liquid formulation is used, then solubility and absorption are improved, but stability and commercial attractiveness deteriorate
Solution Approach 1:
The patent utilizes phase transition by converting the API from a crystalline solid state to an amorphous dispersed state within the polymer matrix. This phase change allows the formulation to maintain liquid-like solubility properties for absorption while presenting as a stable solid dosage form for commercial applications, effectively bridging the gap between liquid and solid formulation advantages.
3Reliability
If solid dispersion is used to enhance dissolution, then absorption is improved, but formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent employs a polymer matrix as an intermediary substance that facilitates the dispersion and stabilization of the amorphous API. This polymer intermediary simplifies the manufacturing process by providing a pre-formed matrix system into which the API can be dispersed, avoiding complex multi-step processes while achieving the desired solid dispersion effect for improved absorption.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures rapid and complete release of the CGRP antagonist, improving bioavailability and overcoming the limitations of poor solubility and thermal degradation, making it suitable for immediate release in migraine therapy.
Implementation Method 1
A tablet formulation comprising a water-soluble polyvinylpyrrolidone/vinyl acetate copolymer matrix with a dispersing agent like TPGS
Implementation Method 2
a disintegration system of powdered sodium chloride and croscarmellose sodium, which achieves complete disintegration within 5 minutes
Implementation Method 3
a dispersing agent like TPGS
Data Source
AI summary
The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API):wherein “Ra” is independently —H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.